The purpose of this study was to validate the automated BPLab ® sphygmomanometer for ambulatory blood pressure monitoring (ABPM) in pregnant women according to Part II of the 1993 British Hypertension Society protocol. Pregnant women attending the antenatal clinic were randomly asked to participate (n=30). The BPLab sphygmomanometer was tested on pregnant women in this study and achieved A/A ratings according to the BHS protocol when compared with the "gold" standard of mercury sphygmomanometry. The device can therefore be recommended for use in pregnancy.
Introduction
Ambulatory blood pressure monitoring (ABPM) has been used in pregnancy for just over a quarter of a century now and is generally accepted in many countries. 1, 2 One purpose of ABPM has been to determine whether there is a significant "white coat" effect among hypertensive pregnant women who appear to have either preeclampsia or gestational hypertension. 1 ABPM is a better predictor than conventional blood pressure (BP) for the development of preeclampsia and adverse pregnancy outcome. [2] [3] [4] [5] It is well-known that hemodynamics in pregnancy is different from in the nonpregnant condition. Circulatory blood volume is increased, which may affect the pulse wave. Perhaps this is one of the reasons that despite the great importance of the ABPM in pregnancy, only a small number of devices have been validated for use in pregnant women according to the British Hypertension Society (BHS) standards. 6 In 2011, the results of validation of the BPLab ® monitor (Petr Telegin LLC, Nizhny Novgorod, Russia) for ABPM in the general population were published. According to the obtained results, the BPLab monitor was assigned to the "A/A" accuracy class for systolic and diastolic BP. 7 We consider those results as a Part I of the evaluation program according to the BHS protocol, and our study as Part II. Thus, the purpose of this study was to validate the device in pregnant women, using mercury sphygmomanometry as the "gold" standard. 
Materials and methods

The tested device
The manufacturer supplied one test device and confirmed that it had been selected from a normal production line.
The sensor of the device is designed to record pulse waves and to measure pressure in the range 0-300 mmHg and pulse rates in the range 20-200 beats/min. The machine inflates the air in the cuff with an automatic pumping system and deflates stepwise (8 mmHg at each step) with an automatic pressure release valve. Four cuffs are available to be used with the device: small, standard, large, and extralarge size. The unit can be powered by two 1.5 V nickel metal hydride (NiMH) 2700-mAh accumulator batteries or two 1.5 V alkaline batteries (type AA). It weighs 180 g and measures 105×85×33 mm. Communication with the personal computer (PC) is provided via Universal Serial Bus (USB) or Bluetooth.
The device was designed for office ("Office" mode) and ambulatory ("ABPM" mode) use. The Office mode was used in this study.
study design
This was validation study of the device using the BHS protocol. 8 The study was approved by the Penza Institute of Advanced Training for Physicians Ethics Committee. Participants were considered to be recruited to the trial if they had provided the signed consent. Recruitment was ad hoc from a population of patients attending routine antenatal clinics at Penza town hospitals. The criteria for exclusion from the study were arrhythmia and sufficiently weak Korotkoff sounds that made acceptable auscultation impossible.
The validation procedure was performed by two medically qualified experts who had been trained using the Compact Disc, read-only-memory (CD-ROM) tutorial detailed on the BHS website. 9 
Data collection
The measurements were taken in the morning in comfortable settings (ambient temperature 22°C-25°C, no stimulatory sights or sounds, etc). The women were seated for at least 5 minutes before taking the measurements. Within this period, the participants were asked their age, height, and weight for the record. Arm circumference was measured at the approximate midpoint of the upper arm to establish the correct size cuff to be used. If the circumference was ,31.5 cm, the standard size cuff was used, and for a circumference between 31.5 and 42 cm, a large cuff was used.
Same-arm, sequential BP measurements were taken alternating between use of a mercury sphygmomanometer (FC-110DELUXE; Focal, Tokyo, Japan) with binaural stethoscope readings (by both observers) and the tested device. The effect of venous congestion and variability of BP was minimized by allowing .30 seconds but ,1 minute between measurements.
The observers were blinded for each other's and the BPLab measurements by positioning the reference device so that each observer could view only the scale of their own device and by ensuring they completed separate forms when writing the results.
The BP of each patient was measured nine times, alternating between the reference measurements and the test device measurements according to the schedule described in the BHS protocol. 8 
Data analysis
The BHS protocol specifies accuracy criteria for interobserver agreement, as follows: for the device to receive an A classification, at least 60% of the differences must show less than or equal to a 5 mmHg difference from the standard device reading, 85% must show less than or equal to a 10 mmHg difference, and 95% must show less than or equal to a 15 mmHg difference. 8 As specified in the BHS protocol, the first and the last recordings from each device were not included, and the remaining seven recordings were used in the analysis.
The BHS protocol dictates that the smaller of the differences between the mercury sphygmomanometer readings at either side of the study device readings are recorded (in mmHg), ignoring the direction of difference. We used for each patient (for systolic BP and diastolic BP, separately) the following formulae:
where BP is the BP measurement result corresponding to the measurement number n.
These differences in readings between the mercury and test devices were categorized into the percentages of BP differences, within 5, 10, and 15 mmHg.
The data were entered into a Microsoft Excel ® spreadsheet, and this program was used for the analysis. Bland-Altman plots were used to determine the limits of agreement between the readings using the mercury and the test devices, and 
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Results
Participants
Pregnant women attending the antenatal clinic were randomly asked to participate. Recruitment continued until all protocolspecified requirements were filled, requiring 33 participants. Three women were excluded because they met criteria for exclusion, leaving the required 30 participants for the analysis. The characteristics of the study group are shown in Table 1 .
In the BHS protocol, the number of subjects required for the validation procedure was reduced from 85 for the main validation test in the Part I to 30 in the Part II. 8 Thus, the number of the participants was sufficient to provide adequate results of the study. Additionally, there was the minimum number of subjects (five) required by BHS protocol within specified BP interval groups (systolic: 100-115,116-130, 131-145, and 146-160 mmHg; diastolic: 70-80, 81-90, and 91-105 mmHg). 8 
Observer agreement
The agreement between observers was well within these limits, and the results are presented in Table 2 .
The BHS protocol specifies that for the device to receive an A classification, at least 60% of the differences must be in the less than or equal to 5 mmHg difference group, 85% in the less than or equal to 10 mmHg group, and 95% in the less than or equal to 15 mmHg category. 8 As we can see, interobserver accuracy was excellent.
Observer-device agreement
The overall result of the validation for both observers is shown in Table 2 . The BHS protocol allows the selection of the results from the best observer, in this case, observer 2. The "final grade" for each systolic and diastolic BP is the better of the grades obtained by the two observers. Thus, the BPLab device achieved an overall A rating (as shown in Table 2 ) for both systolic and diastolic. Figure 1 shows the Bland-Altman plots corresponding to the better observer measurements for diastolic and systolic pressures. Here, the 90 values of the difference between the test device and the readings of the standard device by the better observer (y-axis, in mmHg) are plotted against the mean value of the test device and observer readings (x-axis, in mmHg). The graphs show a random scatter centered about the mean test device-observer difference and no unallowable trends in the data. These are both required features of the Bland-Altman plots for the results to be generalizable. 
Discussion
The oscillometric BPLab BP monitor has been validated in adult and pediatric population achieving similar results to those we have described. 7, 11 Moreover, the device was validated for measuring central aortic pressure and parameters of arterial stiffness. [12] [13] [14] It provides normative data for arterial stiffness and central BP indices and allows studying the feasibility of BPLab indices in daily life dynamic conditions. 15, 16 We believe that this is an additional advantage of BPLab use for ABPM in the antenatal clinic, in the pregnancy day assessment unit, or when admitted to the antenatal ward for hypertension management.
limitations of the study
There were no deviations from the standard procedure described by BHS protocol. However articles have discussed some of the limitations of the use of this protocol for the study of ABPM devices, and these should be noted.
17,18
Conclusion
The automated BPLab sphygmomanometer for ABPM was tested on pregnant women in this study and achieved A/A ratings according to the BHS protocol when compared with the gold standard of mercury sphygmomanometry. The device can therefore be recommended for use in pregnancy.
Disclosure
The authors report no conflicts of interest in this work. 
Vascular Health and Risk Management
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/vascular-health-and-risk-management-journal Vascular Health and Risk Management is an international, peerreviewed journal of therapeutics and risk management, focusing on concise rapid reporting of clinical studies on the processes involved in the maintenance of vascular health; the monitoring, prevention and treatment of vascular disease and its sequelae; and the involvement of metabolic disorders, particularly diabetes. This journal is indexed on PubMed Central and MedLine. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. 
